Table 1.

Functional properties of FIXa variants with substitutions in exosite II

FIXa variantAmidolytic activityFX activation in the absence of FVIIIaFX activation in the presence of FVIIIa
Apparent Km (mM)kcat (s−1)Apparent Km (nM)103 × kcat (min−1)Apparent Km (nM)kcat (min−1)
wt-FIXa 2.1 ± 0.3 13.2 ± 0.5 91 ± 6 25 ± 1 19 ± 6 54 ± 4 
FIXaK126ACT 2.4 ± 0.3 10.9 ± 1.7 83 ± 19 15 ± 1 4 ± 1 26 ± 1 
FIXaR165ACT 3.6 ± 0.5 11.1 ± 0.8 55 ± 9 7 ± 1 ND ND 
FIXaR170ACT 1.7 ± 0.2 11 ± 0.8 68 ± 15 17 ± 1 20 ± 6 100 ± 7 
FIXaK173ACT 1.9 ± 0.2 9.3 ± 0.6 82 ± 12 11 ± 1 9 ± 5 39 ± 2 
FIXaK230ACT 3.9 ± 0.7 13.3 ± 2.8 53 ± 13 14 ± 1 9 ± 2 30 ± 2 
FIXaR233ACT 2.8 ± 0.3 11.4 ± 1.3 90 ± 24 14 ± 1 3 ± 1 17 ± 1 
FIXaR165A+R233ACT 9.6 ± 3.3 14.2 ± 0.8 61 ± 14 5 ± 1 ND ND 
FIXa variantAmidolytic activityFX activation in the absence of FVIIIaFX activation in the presence of FVIIIa
Apparent Km (mM)kcat (s−1)Apparent Km (nM)103 × kcat (min−1)Apparent Km (nM)kcat (min−1)
wt-FIXa 2.1 ± 0.3 13.2 ± 0.5 91 ± 6 25 ± 1 19 ± 6 54 ± 4 
FIXaK126ACT 2.4 ± 0.3 10.9 ± 1.7 83 ± 19 15 ± 1 4 ± 1 26 ± 1 
FIXaR165ACT 3.6 ± 0.5 11.1 ± 0.8 55 ± 9 7 ± 1 ND ND 
FIXaR170ACT 1.7 ± 0.2 11 ± 0.8 68 ± 15 17 ± 1 20 ± 6 100 ± 7 
FIXaK173ACT 1.9 ± 0.2 9.3 ± 0.6 82 ± 12 11 ± 1 9 ± 5 39 ± 2 
FIXaK230ACT 3.9 ± 0.7 13.3 ± 2.8 53 ± 13 14 ± 1 9 ± 2 30 ± 2 
FIXaR233ACT 2.8 ± 0.3 11.4 ± 1.3 90 ± 24 14 ± 1 3 ± 1 17 ± 1 
FIXaR165A+R233ACT 9.6 ± 3.3 14.2 ± 0.8 61 ± 14 5 ± 1 ND ND 

Catalytic efficiency of FIXa variants of the exosite II was evaluated toward varying concentrations of the peptide substrate CH3SO2-(D)-CHG-Gly-Arg-pNA (indicated as amidolytic activity) and of the natural substrate FX in the presence of phospholipids and Ca2+ ions in the absence and presence of FVIIIa. Experimental conditions are given in “Materials and methods” and in the legend to Figure 5. Data were fitted in the Michaelis-Menten equation to obtain Km and kcat values. Kinetic parameters represent the mean ± standard deviation of 2 to 3 independent experiments.

ND, not determined because of substrate inhibition; see Figure 5C.

Close Modal

or Create an Account

Close Modal
Close Modal